Pro­to­cols: Ed­i­tas adds CRISPR/Cas9 IP; biosim­i­lars make fresh gains in U.S. mar­ket

Ed­i­tas $ED­IT has picked up some fresh CRISPR/Cas9 IP from Mass Gen­er­al. The gene edit­ing pi­o­neer, which has fo­cused on adding fresh tech in the race to get pro­grams in­to the clin­ic, says the deal adds “high-fi­deli­ty Cas9 nu­cle­as­es and Cas9 PAM vari­ants that will en­able the Com­pa­ny to ad­dress an ex­pand­ed range of ge­net­i­cal­ly-de­fined dis­eases with the po­ten­tial for en­hanced speci­fici­ty.”

Any­one look­ing for fresh ev­i­dence of the im­pact biosim­i­lars will have on brand­ed drugs should look to the lat­est news from CVS, which just replaced Sanofi’s Lan­tus with a cheap­er copy­cat from Eli Lil­ly on its for­mu­la­ry. Drug buy­ers will have lit­tle trou­ble forc­ing pa­tients to take less ex­pen­sive biosim­i­lars in the U.S., which will help ac­cel­er­ate rapid adop­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.